Expanding Access to Cutting-Edge Cancer Trials: START and OneOncology Launch New Sites in California
Los Angeles, CA – A significant advancement in cancer research and patient access to innovative therapies is underway as the START Center for Cancer Research (START) and OneOncology announce a strategic partnership to establish three new early-phase clinical trial sites across the United States. This collaboration aims to accelerate the development of novel cancer treatments and bring them to patients sooner.
The first of these sites will be located within the Los Angeles Cancer Network (LACN) in California. This marks a crucial expansion of START's network, bringing its expertise in early-phase clinical trials to a region with a high prevalence of cancer and a strong commitment to research. The partnership will also include sites in [mention other locations if available, otherwise state: 'additional locations to be announced soon'].
Why Early-Phase Trials Matter
Early-phase clinical trials, often referred to as Phase 1 and Phase 2 trials, are critical for evaluating the safety and efficacy of new cancer drugs and therapies. These trials are typically conducted before a treatment becomes widely available, and they represent a vital step in the drug development process. They allow researchers to determine the appropriate dosage, identify potential side effects, and gain initial insights into whether the treatment shows promise in fighting cancer.
The Power of the Collaboration
START Center for Cancer Research is renowned for its expertise in designing and conducting early-phase oncology trials. They bring a wealth of scientific knowledge and a proven track record of successful trial execution. OneOncology, on the other hand, is a rapidly growing network of oncology practices that provides unparalleled access to patients and a deep understanding of the needs of the oncology community.
“This partnership with OneOncology is a game-changer for our ability to bring innovative cancer therapies to patients,” says [Quote from START representative, if available. Otherwise: 'A spokesperson for START stated']. “By leveraging OneOncology’s extensive network and clinical expertise, we can significantly expand our reach and accelerate the development of life-saving treatments.”
OneOncology’s CEO, [Name of CEO], added, “We are thrilled to collaborate with START to expand access to cutting-edge clinical trials for our patients. This partnership aligns perfectly with our mission to provide the highest quality cancer care and to advance the field of oncology through research.”
Benefits for Patients and the Future of Cancer Care
The launch of these new clinical trial sites offers several key benefits:
- Increased Access: More patients in California and potentially across the US will have the opportunity to participate in early-phase cancer trials.
- Accelerated Research: The collaboration will speed up the development of new cancer therapies.
- Improved Outcomes: Early access to innovative treatments can lead to better outcomes for patients battling cancer.
The partnership between START and OneOncology represents a significant step forward in the fight against cancer, promising a future where patients have access to the most advanced and promising treatments available.
Learn More:
